Curon Medical, Inc. Approved For Listing On Nasdaq Bulletin Board

FREMONT, Calif., July 28 /PRNewswire-FirstCall/ -- Curon Medical, Inc. today announced that its common stock listing application has been approved by the NASDAQ for trading on the OTC Bulletin Board. Most recently traded as CRNM.PK on the OTC Pink Sheets, and previous to that as CURN on the NASDAQ Small Cap National Market, the Company's common stock is now trading on the NASD Over the Counter Bulletin Board (OTCBB) under the stock symbol CRNM.OB.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050318/CURONLOGO )

"The transition from the OTC Pink Sheets to the NASDAQ OTC Bulletin Board is an exciting development for us," commented Larry C. Heaton II, President and Chief Executive Officer of Curon Medical. "Our shareholders should benefit from this listing through more efficient trading, and, potentially, increased liquidity in Curon Medical stock by allowing for a greater range of potential investors and more attention from the investment community."

The OTC Bulletin Board, administered by the NASDAQ Stock Market for the National Association of Securities Dealers (NASD), is a regulated quotation service that displays real-time quotes, last-sale prices and volume information in over-the-counter equity securities. OTCBB securities include national, regional, and foreign equity issues, warrants, units, ADRs, and Direct Participation Programs (DPPs). Information regarding the OTC Bulletin Board can be found on its website at http://www.otcbb.com .

About Curon Medical, Inc.

Curon Medical develops, manufactures and markets innovative proprietary products for the treatment of gastrointestinal disorders. The Company's products and products under development consist of radiofrequency generators and single use disposable devices. Its first product, the Stretta System, received U.S. Food and Drug Administration clearance in April 2000 for the treatment of gastroesophageal reflux disease, commonly referred to as GERD. The Company's Secca System for the treatment of bowel incontinence received clearance from the FDA in March 2002. For more information on the Company or its products, please visit the Company's website at http://www.curonmedical.com .

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, specifically, statements concerning trading efficiency, stock liquidity and investment community attention are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary, expectations and are subject to risks and uncertainties, which may cause the Company's actual results to differ materially from the statements contained herein. Further information on potential risk factors that could affect the Company, its business and its financial results are detailed in the Company's periodic filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled, "Management's Discussion and Analysis of Financial Condition and Results of Operations -- Factors Affecting Future Results," in Curon's quarterly report of Form 10-Q for the fiscal quarter ended March 31, 2006 filed with the Securities and Exchange Commission on May 15, 2006. The forward-looking statements are made as of July 27, 2006, and the Company undertakes no obligation to release publicly any revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050318/CURONLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comCuron Medical, Inc.

CONTACT: Larry C. Heaton II, President and Chief Executive Officer,+1-510-661-1801, lheaton@curonmedical.com, or Alistair F. McLaren, VicePresident, Chief Financial Officer, +1-510-661-1803;amclaren@curonmedical.com, both of Curon Medical, Inc.; or InvestorRelations, Melody A. Carey of Rx Communications Group, LLC,+1-917-322-2571, mcarey@rxir.com

Web site: http://www.curonmedical.com/